Edesa Biotech

EDSA · NASDAQ

$2.77+$0.01 (+0.36%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $2.76

EDSA analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $13.77 (+397.1% upside)

Low: $5.05
Now: $2.77
High: $22.05

Upgrades and downgrades

The latest rating actions, newest first

EDSA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Nov 3, 2025	Maintains	Buy	$5.00	40%

The case for and against

Updated Dec 15, 2025

Bull case

Edesa Biotech Inc's EB01 demonstrated significant improvements in skin health for allergic contact dermatitis (ACD) patients in a Phase 2b trial, indicating the potential for a safer alternative to traditional corticosteroids and calcineurin inhibitors. The ongoing exploration of its drug candidates, including EB05 and EB07, presents opportunities for expansion into new indications and markets, which could enhance projected sales and revenue growth. With a successful track record in clinical trials and a robust pipeline, Edesa Biotech is well-positioned for potential financial gains in the biotechnology sector focused on treating immune-related diseases.

Bear case

Edesa Biotech is projected to experience continued negative cash flows from operating activities through FY2025 and FY2026, indicating a prolonged financial strain. Additionally, the company has faced challenges in its clinical trials, including a higher-than-expected dropout rate that could hinder the progress of its product pipeline. With operating cash flows reported as negative in FY2024, financial stability appears to be a significant concern for the company's future growth prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.